Abstract
Prevention of cardiovascular disease (CVD) is an important therapeutic object of diabetes care. This study assessed whether an index based on plasma free amino acid (PFAA) profiles could predict the onset of CVD in diabetic patients. The baseline concentrations of 31 PFAAs were measured with high-performance liquid chromatography-electrospray ionization-mass spectrometry in 385 Japanese patients with type 2 diabetes registered in 2001 for our prospective observational follow-up study. During 10 years of follow-up, 63 patients developed cardiovascular composite endpoints (myocardial infarction, angina pectoris, worsening of heart failure and stroke). Using the PFAA profiles and clinical information, an index (CVD-AI) consisting of six amino acids to predict the onset of any endpoints was retrospectively constructed. CVD-AI levels were significantly higher in patients who did than did not develop CVD. The area under the receiver-operator characteristic curve of CVD-AI (0.72 [95% confidence interval (CI): 0.64–0.79]) showed equal or slightly better discriminatory capacity than urinary albumin excretion rate (0.69 [95% CI: 0.62–0.77]) on predicting endpoints. A multivariate Cox proportional hazards regression analysis showed that the high level of CVD-AI was identified as an independent risk factor for CVD (adjusted hazard ratio: 2.86 [95% CI: 1.57–5.19]). This predictive effect of CVD-AI was observed even in patients with normoalbuminuria, as well as those with albuminuria. In conclusion, these results suggest that CVD-AI based on PFAA profiles is useful for identifying diabetic patients at risk for CVD regardless of the degree of albuminuria, or for improving the discriminative capability by combining it with albuminuria.
Highlights
Cardiovascular disease (CVD) is a life-threatening complication in patients with diabetes
We found that the cardiovascular disease-amino acid based index (CVD-AI) could distinguish cases from controls even when patients with normoalbuminuria (AUC: 0.66, 95% confidence interval (CI): 0.54–0.77, P = 0.007) and those with albuminuria (AUC: 0.72, 95% CI: 0.62–0.83, P,0.001) were separately analyzed (Figure 1)
Using high-throughput plasma free amino acid (PFAA) profiling and the data of our ongoing prospective observational follow-up study we constructed the diagnostic index, the CVD-AI, to predict the onset of CVD in patients with type 2 diabetes. This predictive effect was independent of the levels of albuminuria and the conventional risk factors of CVD, indicating that altered PFAA profiles were able to effectively identify high risk patients, even those without albuminuria. These findings suggest that the PFAA profile is a clinically useful index for improving the discriminative capability for coronary artery disease in diabetic patients in addition to conventional risk factors and better risk stratification even among those with normoalbuminuria, who are at relatively low risk for CVD
Summary
Cardiovascular disease (CVD) is a life-threatening complication in patients with diabetes. The development of biomarkers or an index to identify patients at high risk for CVD is clinically important as it makes possible the initiation of adequate medication for patients at risk. The prevention and reduction of albuminuria by intensive control of the above-mentioned conventional risk factors for CVD is considered an important therapeutic target in the care of patients with diabetes [2,6,7]. Despite these efforts, many patients still develop CVD, suggesting that only the evaluation of known risk factors is insufficient to distinguish between patients at high and low risk of CVD.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
